DV
Dividend Vision

CTMX — CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. (CTMX)

Total return is -74.0% over the past 10.9 years, 434.4 points behind SPY at 360.4%. Its deepest 1-year drawdown was 56.9%.

CytomX Therapeutics is an oncology-focused biopharmaceutical company developing biologics for treating solid tumors and the tumor microenvironment, leveraging its conditional activation and PROBODY platform technologies to create antibody-drug conjugates, T-cell engagers, and immune modulators; the company maintains strategic collaborations with major partners including Amgen, Bristol Myers Squibb, Regeneron, and Moderna. As a development-stage biotech company, CytomX does not currently pay distributions and carries the inherent risks of clinical-stage drug development with no approved products yet generating revenue. The company appeals primarily to investors with high risk tolerance who are focused on long-term capital appreciation potential in the oncology therapeutics space.

CTMX key facts

Asset type
Stock
Asset class
Equity
Inception date
10/08/2015
Distribution frequency
None
Last close
$3.36
Market cap
$732,141,568
Average volume
1433000.0
Beta
2.138
Payout ratio
0.0
Forward P/E
14.2045
EPS
$-0.57